AtriCure’s (ATRC) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of AtriCure (NASDAQ:ATRCFree Report) in a research report released on Monday,Benzinga reports. They currently have a $60.00 target price on the medical device company’s stock.

ATRC has been the topic of a number of other reports. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Needham & Company LLC raised their target price on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. restated an “overweight” rating and set a $40.00 price objective on shares of AtriCure in a research note on Tuesday, December 17th. Oppenheimer lifted their price objective on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, UBS Group lifted their price objective on shares of AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.44.

Check Out Our Latest Stock Report on AtriCure

AtriCure Stock Performance

ATRC stock opened at $42.36 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -51.04 and a beta of 1.46. AtriCure has a 1 year low of $18.94 and a 1 year high of $43.11. The stock’s fifty day moving average is $35.39 and its two-hundred day moving average is $31.09.

Hedge Funds Weigh In On AtriCure

Institutional investors have recently bought and sold shares of the stock. State Street Corp increased its stake in AtriCure by 4.9% in the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after purchasing an additional 63,002 shares in the last quarter. Geode Capital Management LLC increased its stake in AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after purchasing an additional 32,676 shares in the last quarter. Atom Investors LP purchased a new position in AtriCure in the 3rd quarter worth about $1,741,000. SG Americas Securities LLC purchased a new position in AtriCure during the 3rd quarter valued at about $488,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in AtriCure by 31.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock valued at $14,038,000 after acquiring an additional 119,929 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

See Also

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.